Purchase this article with an account.
Jorge E. Peraza Nieves, Johnny Javier Castellar Cerpa, Paula Arribas Pardo, Paula Bañeros, Juan Antonio Troyano Rivas, Angel Romo Lopez; Endonasal mitomicyn-C during diode laser transcanalicular dacryocystorhinostomy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3046.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the benefit of endonasal topical application of mitomycin-C in patients undergoing transcanalicular diode laser dacryocystorhinostomy (DL-DCR).
We carried out a retrospective descriptive study of 400 patients who underwent transcanalicular DL-DCR. The procedure was performed under local anesthesia. In 30 patients, endonasal mitomycin-C (0.4 mgr/0.2 ml) was administered during the surgical intervention and in 370 any anti-cicatricial agent was used. We compared the lacrimal permeability by syringing lacrimal pathway, after 12 months of performing surgery. The results were compared using the Chi-squared test with the Yates correction.
The average follow-up was 12 months (range 6 to 18 months). Of the 370 patients who underwent DCR without mitomycin-C, 34 failed after a year of surgery. Only one failed of the 30 patients treated with mitomycin-C. We found a statistically significant association between mitomycin-C used procedure and lacrimal permeability after 12 months of performing surgery (p<0.05).
In our study, the administration of topical endonasal mitomycin-C during transcanalicular diode laser dacryocystorhinostomy is associated to permeability of nasolacrimal duct . It is a minimally invasive quick procedure yielding a high success rate. We did not find secondary effects due to application of mitomcyn-C.
This PDF is available to Subscribers Only